Although important advances have been achieved in BCC via targeted treatments that inhibit Sonic Hedgehog signaling, an inhibitor of immune checkpoints such as cemiplimab (anti-PD-1/PD-L1) may have promising outcomes [116,117]. Here, PDCD1 is linked to skin basal cell carcinoma.